Overview of the Price Target Adjustment#
Truist Securities has reduced its price target for National Health Investors (NHI) from $92 to $89 while maintaining a Buy rating. Currently, NHI's stock is trading at $78.03, which is below the new target. Analysis from InvestingPro suggests that the stock may be slightly overvalued at this price.
Details of the Asset Sale#
The adjustment in price target follows NHI's announcement of a deal to sell a portfolio that includes 32 skilled nursing facilities and three independent living facilities to National HealthCare Corporation for $560 million. This sale is significant as it represents a 7.1% cash cap rate, which is a measure of the return on investment based on the income generated by the properties.
NHI anticipates incurring transaction costs between $6 million and $8 million and expects the sale to close on July 1, 2026. This transaction also alleviates uncertainty regarding the lease maturity of National HealthCare Corporation at the end of this year, addressing concerns about the future of the portfolio.
Financial Performance and Analyst Ratings#
Following the announcement of the asset sale, Truist has lowered its estimates for funds from operations (FFO) for NHI. FFO is a key metric used to evaluate the performance of real estate investment trusts (REITs) like NHI, as it reflects the cash generated from operations.
In related news, NHI reported its fourth-quarter 2025 earnings, which exceeded analysts' expectations. The company posted earnings per share of $0.80, slightly above the forecast of $0.79, and revenue of $105.8 million, significantly higher than the anticipated $73.55 million, marking a remarkable surprise of 43.85%.
Additionally, Cantor Fitzgerald has reiterated an Overweight rating for NHI with a price target of $94, citing favorable market conditions for the company’s senior housing portfolio. These developments underscore NHI's strategic decisions and financial performance in the current market.